Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 21, 2014
Pharmacy Choice - News - Front Page Healthcare News - December 21, 2014

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/21/14 - ArtVentive Medical Secures FDA Clearance for EOS Device [Manufacturing Close - Up]
ArtVentive Medical Group recently received U.S. Food and Drug Administration clearance for the Endoluminal Occlusion System. Anthony Venbrux, Interventional Radiologist at The George Washington University Hospital in Washington, D.C. "In my experience with the device, it has shown immediate and complete vascular occlusion upon deployment.
12/21/14 - Incyte Gets FDA Approval for Jakafi (ruxolitinib) [Professional Services Close - Up]
Incyte Corp. recently reported that the U.S. Food and Drug Administration has approved Jakafi for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi, an oral medication, is the first and only product approved by the FDA for PV, a rare and progressive blood cancer.
12/21/14 - Incyte: U.S. Food and Drug Administration Approves Jakafi for Uncontrolled Polycythemia Vera [Professional Services Close - Up]
Incyte Corp. recently reported that the U.S. Food and Drug Administration has approved Jakafi for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. In a release, the Company noted that PV is a rare and progressive blood cancer. For the first time we are able to provide these pa
12/21/14 - Jazz Pharmaceuticals Enrolls Patients in Xyrem (Sodium Oxybate) Trial [Professional Services Close - Up]
According to a release from Jazz Pharmaceuticals, Xyrem is the only U.S. Food and Drug Administration approved treatment for narcolepsy with cataplexy in adults. "Narcolepsy with cataplexy is a debilitating, chronic condition that commonly begins in childhood, yet there are no approved cataplexy treatments for patients under the age of 18," said J
12/21/14 - Mylan Gets Tentative FDA Approval for Paediatric Formulations of Abacavir/lamivudine [Professional Services Close - Up]
Mylan recently reported that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. Dominique Limet, CEO ViiV Healthcare commented
12/21/14 - News from Annals of Internal Medicine Dec. 2, 2014
By a News Reporter-Staff News Editor at VerticalNews Health& Science 1. Better glucose control in midlife may protect against cognitive decline later in life. Having diabetes or prediabetes in midlife is associated with a greater risk for cognitive decline later in life, according to a study published in Annals of Internal Medicine. For a PDF, pl
12/21/14 - Studies from University of Tennessee Yield New Data on Public Policy (Principles in Action: An Examination of Food and Drug Administration Letters...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Data detailed on Public Policy have been presented. For more information on this research see: Principles in Action: An Examination of Food and Drug Administration Letters Involving Violative Internet Promotions from 1997 to 2012. Journal of Public Policy& Marketing, 2014; 33:
12/21/14 - Study Results from Heart Hospital Provide New Insights into Acute Coronary Syndrome (The Management of Acute Coronary Syndromes in Patients With...
By a News Reporter-Staff News Editor at Heart Disease Weekly Research findings on Heart Diseases and Conditions are discussed in a new report. According to news reporting from Plano, Texas, by NewsRx journalists, research stated, "Coronary heart disease is highly prevalent in patients with CKD, and survival after acute coronary syndrome is worse
12/21/14 - Sunovion Pharmaceuticals Submits Supplemental Drug Application to FDA for Approval [Professional Services Close - Up]
Sunovion Pharmaceuticals recently reported that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration seeking approval for the use of Aptiom as monotherapy treatment of partial-onset seizures. "Sunovion has a deep commitment to helping address the unmet medical needs of people living with partial-onset seizu
12/21/14 - The Gleaner, Henderson, Ky., Chuck Stinnett column [The Gleaner, Henderson, Ky.]
Dec. 21 HENDERSON, Ky. Owensboro Health has had a presence in Henderson for nearly five years with its walk-in clinic at Walmart. "We believe Henderson is one of our important communities," Owensboro Health President and CEO Philip Patterson said. Methodist Hospital CEO Bruce Begley disagrees, saying in a statement: "The recently established a
12/20/14 - Actavis Considers Offer For Almirall : Report
MADRID- Generic drug maker Actavis plc is considering Spanish drugmaker Almirall SA as one of several possible takeover targets, Bloomberg reported citing people familiar with the matter said. The report said that Actavis has identified Almirall, which could be valued at about 3 billion euros or $3.7 billion in a deal, as one of its preferred targe
12/20/14 - HeartFlow Secures De Novo Clearance from the U.S. Food and Drug Administration for Breakthrough FFRCT Technology
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, announced that it received de novo clearance from the U.S. Food and Drug Administration for its FFRCT technology. HeartFlow FFRCT is the first and only non-invasive imaging technology for
12/20/14 - Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze (asparaginase Erwinia chrysanthemi)
Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze . "Administration of Erwinaze through an intravenous infusion provides physicians another option for patients, including those who cannot tolerate intramuscular injections," said Jeffrey Tobias, M.D., executiv
12/20/14 - Local hospitals dinged by Medicare [The Morning Call (Allentown, Pa.)]
Lehigh Valley Hospital's Salisbury, Allentown and Bethlehem locations and St. Luke's University Hospital in Bethlehem, as well as the Surgical Specialty Center at Coordinated Health in Allentown are among more than 700 hospitals across the country whose Medicare reimbursement rates will be cut by 1 percent, the Centers for Medicare and Medicaid Ser
12/19/14 - 8 Western Pennsylvania hospitals penalized over infections [The Pittsburgh Tribune-Review]
Dec. 19 Eight hospitals in Western Pennsylvania were penalized by the federal government because patients were infected while being treated at their facilities. The hospitals are among more than 700 across the country whose Medicare reimbursement rates will be cut by 1 percent for not reducing hospital-acquired infections, the Department of Healt
12/19/14 - AbbVie Receives U.S. FDA Approval of VIEKIRA PAK? (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK?, an all-oral, interferon-free treatment, with or without ribavirin, for the treatment of patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis. "We are proud of the work of our research and development organization to bri
12/19/14 - Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
Amarantus BioScience Holdings, Inc., a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food& Drug Administration for Orphan Drug Designation for its investigation
12/19/14 - As December 20 Deadline Nears for Enrollment Under the Affordable Care Act, a Health Insurance Expert from MetroPlus Health Plan Answers Common Questions
December 20 is the deadline for enrollment at the NY State of Health online marketplace for residents who want their health coverage to begin January 1, 2015. With the current enrollment window closing soon, Seth Diamond, Chief Operating Officer at MetroPlus Health Plan, answered questions that many New Yorkers still have about the Affordable Care
12/19/14 - AstraZeneca cancer drug, companion test approved
TRENTON, N.J. U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC. The Food and Drug Administration also approved a companion diagnostic test from Myriad Genetics Inc. of Salt Lake City called BRACAnalysis CDx. Richard Pazdur, dir
12/19/14 - AstraZeneca receives thumbs up for drug
DRUG maker AstraZeneca rewarded the faith of investors in the company yesterday after its pioneering ovarian cancer drug was approved for use across Europe. The FTSE 100 pharmaceutical company highlighted its industry-leading cancer drugs earlier this year to counter a 70 bn takeover bid from US rival Pfizer. News of the European Commission'' s a
12/19/14 - AstraZeneca's Lynparza Gets US FDA Approval For Ovarian Cancer
LONDON- AstraZeneca PLC said Friday that the US Food and Drug Administration has approved Lynparza as a monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. The FDA approval follows the approval of the drug in the EU as
12/19/14 - Bio2 Technologies, Inc. Announces Receipt of FDA 510(k) Clearance for CLM Bioactive Scaffold
Bio2 Technologies, Inc. announced today that it has received 510 clearance from the U.S. Food and Drug Administration for its CLM Bioactive Scaffold. Paul Nichols, President and Chief Executive Officer of Bio2 Technologies, stated "the receipt of FDA market clearance paves the way for U.S. commercialization of our first product line, resorbable b
12/19/14 - Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant Patient Benefits Demonstrated by Company's Leading Contact Force Therapy
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the BIOSENSE WEBSTER ADVANTAGE SM Program, an outcomes-based, risk-sharing program for U.S. hospitals that reinforces the significant patient benefits demonstrated by the company s THERMOCOOL SMARTTOUCH Catheter.
12/19/14 - Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd.
Breckenridge Pharmaceutical, Inc. announced today that it has entered into a multi-product agreement with MSN Laboratories Pvt. Ltd. under which Breckenridge and MSN expect to commercialize several new ANDAs. Under the terms of the agreement, MSN will develop, manufacture, and supply the products exclusively to Breckenridge for the U.S. market, a
12/19/14 - Centene's Behavioral Health Subsidiary Awarded Expanded Contract In Southern Arizona
Centene Corporation announced today that its behavioral health management company, Cenpatico of Arizona, in partnership with University of Arizona Health Plan, has been selected by the Arizona Department of Health Services/Division of Behavioral Health Services to be the Regional Behavioral Health Authority for the new southern geographic service
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
Medication Errors: A Patient Safety and Quality Improvement Program
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415